The field has moved fast. Not long ago longevity was treated as a curiosity; now Longevity's a real investment category, on track to reach $67B by 2035. That shift is the thing worth paying attention to. The good companies aren't selling immortality. They're going after healthspan, treating aging as a root cause, and measuring themselves against clinical results.

Across Southeast Asia, longevity is not yet a system — it is a signal. From Singapore’s clinical precision to Thailand’s hospitality-led wellness, from Malaysia’s medical value positioning to lifestyle demand in Indonesia and Vietnam, the region is experiencing rapid growth without uniform integration. This imbalance is precisely what makes Southeast Asia one of the most compelling longevity frontiers in Asia today.